<DOC>
	<DOCNO>NCT01081639</DOCNO>
	<brief_summary>This prospective , randomise , open comparative monocentric phase IIIb study evaluate convenience , safety efficacy follitropin alfa ( Gonal-f ) liquid pen compare follitropin beta ( Puregon ) liquid pen .</brief_summary>
	<brief_title>To Evaluate Convenience , Safety Efficacy Follitropin Alfa Liquid Pen Compared With Follitropin Beta Liquid Pen</brief_title>
	<detailed_description>Treatment subfertility infertility assist reproduction technology ( ART ) in-vitro fertilisation ( IVF ) embryo transfer ( ET ) require multiple follicular development increase number female gamete , chance successful treatment outcome . Ovarian stimulation IVF/intracytoplasmic sperm injection ( ICSI ) currently include suppression endogenous luteinizing hormone ( LH ) secretion administration gonadotrophin release hormone ( GnRH ) agonist , follow stimulation multiple follicular development exogenous FSH administration . When adequate follicular development achieve , single dose u-hCG ( urinary-hCG ) administer mimic endogenous LH surge induce final oocyte maturation . Recombinant-human FSH ( r-hFSH ) show superior u-hFSH term require few ampule efficacious term number oocyte recover term pregnancy rate . Recently , new formulation follitropin alfa develop due general trend field therapeutic recombinant protein move presentation base biological activity presentation base physico-chemical characteristic . Until follitropin alfa produce powder injection ( either monodose multidose preparation ) glass ampoule glass vial administer use plastic glass syringe . Serono develop multidose solution injection prefilled disposable injection pen . This study involve compare administration follitropin alfa liquid formulation apply pen follitropin beta liquid formulation also apply pen . OBJECTIVES The objective study evaluate convenience , safety efficacy Follitropin alfa ( Gonal-f ) liquid pen compare Follitropin beta ( Puregon ) liquid pen .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Premenopausal woman , 18th 39th birthday , receive recombinant FSH stimulation IVF and/or ICSI Subjects able communicate well investigator comply requirement entire study Subjects give write informed consent , prior treatment , understanding consent may withdraw subject time without prejudice Subjects know allergic reaction one ingredients Subjects enlarge ovary cyst unrelated polycystic ovary ( PCO ) Subjects gynaecological bleed unknown origin Subjects ovarian , uterine , mammary cancer Subjects tumor hypothalamus pituitary gland</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Follitropin alfa</keyword>
	<keyword>Follitropin beta</keyword>
	<keyword>Fertilization , vitro</keyword>
	<keyword>Intracytoplasmic sperm injection</keyword>
	<keyword>Assisted reproductive technique</keyword>
	<keyword>Polycystic ovary syndrome</keyword>
</DOC>